Orbital exenteration: an updated review with perspectives.

Eye-sparing surgery Orbital exenteration Orbital reconstruction Orbital socket Overall survival

Journal

Survey of ophthalmology
ISSN: 1879-3304
Titre abrégé: Surv Ophthalmol
Pays: United States
ID NLM: 0404551

Informations de publication

Date de publication:
Historique:
received: 04 09 2020
revised: 17 01 2021
accepted: 18 01 2021
pubmed: 2 2 2021
medline: 24 3 2022
entrez: 1 2 2021
Statut: ppublish

Résumé

Orbital exenteration is a radical and disfiguring surgery mainly performed in specialized tertiary care centers. Orbital exenteration has long been considered the treatment of choice for managing periocular tumors invading the orbit or primary orbital malignancies. Over the past decades, attention has been directed toward reducing the perioperative morbidity by developing new surgical devices and new strategies and promoting cosmetic rehabilitation by providing adequate facial prostheses. Despite these advances, several studies have questioned the role of orbital exenteration in improving overall survival. The last decade has been marked by the emergence of a new paradigm: the "eye-sparing" strategies based on conservative surgery with or without adjuvant radiotherapy and/or targeted therapies and immunotherapies. We summarize the data on orbital exenteration, including epidemiology, etiologies, use of surgical ablative and reconstructive techniques, complications, outcomes, and the related controversies.

Identifiants

pubmed: 33524457
pii: S0039-6257(21)00020-5
doi: 10.1016/j.survophthal.2021.01.008
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

856-876

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of competing interest None of the authors have competing interests to declare.

Auteurs

Arnaud Martel (A)

Université Côte d'Azur, Ophthalmology department, Centre Hospitalier Universitaire de Nice, Nice, France. Electronic address: martel.a@chu-nice.fr.

Stephanie Baillif (S)

Université Côte d'Azur, Ophthalmology department, University Hospital of Nice, Nice, France.

Sacha Nahon-Esteve (S)

Université Côte d'Azur, Ophthalmology department, Centre Hospitalier Universitaire de Nice, Nice, France.

Lauris Gastaud (L)

Oncology department, Antoine Lacassagne Cancer Centre, Nice, France.

Corine Bertolotto (C)

Université Côte d'Azur, INSERM, C3M, Nice, France.

Sandra Lassalle (S)

Laboratory of Clinical and Experimental Pathology and Biobank BB-0033-00025, Nice, France.

Jacques Lagier (J)

Université Côte d'Azur, Ophthalmology department, University Hospital of Nice, Nice, France.

Mehrad Hamedani (M)

Oculoplastic department, Jules Gonin Eye hospital, Lausanne, Switzerland.

Gilles Poissonnet (G)

Cervico-facial department, Institut Universitaire de la Face et du Cou, Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH